<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525016</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0057</org_study_id>
    <nct_id>NCT02525016</nct_id>
  </id_info>
  <brief_title>Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery</brief_title>
  <acronym>SPIRAL</acronym>
  <official_title>Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous lidocaine is efficient for management of post operative pain in abdominal
      surgery. As previously published in literature the investigators use it during bariatric
      surgery.

      Nevertheless plasmatic concentration of lidocaine is unknown in this population, despite a
      widespread use.

      Investigators propose in this work to bring an objective proof that administration of
      lidocaine based on a modified body weight is safe.

      Intravenous administration concerned the peri operative period. A total of six samples are
      taken for each patient.

      Investigators get approbation of local ethic committee for this work.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasmatic concentration of lidocaine</measure>
    <time_frame>From bolus to day 1 after cessation of administration</time_frame>
    <description>Blood samples will be removed by the peripheral catheter or direct venous puncture with other blood sample usually performed during post-operative period.
First sample will be taken after initial bolus (ie 10 min after initiation of perfusion), second at 20 min, third at 30 min. The fourth and fifth samples will be taken after change of posology (from 2 to 1 mg/kg/h at the end of surgery) and at the end of administration. The sixth sample will be performed the day after the end of administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>occurence of adverse events related to lidocaine use</measure>
    <time_frame>Up to 2 days after surgery</time_frame>
    <description>neurologic (seizure, dysgeusia, dizziness) or cardiologic events (atrio ventricular block, ventricular rhythm disorder) will be assessed after surgery, during hospitalization in post-operative room or intensive care unit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Obesity</condition>
  <condition>Bariatric Surgery</condition>
  <arm_group>
    <arm_group_label>assessment of plasmatic lidocaine rate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <arm_group_label>assessment of plasmatic lidocaine rate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <arm_group_label>assessment of plasmatic lidocaine rate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult who perform a bariatric surgery (sleeve, by-pass, mini by-pass) under
             laparoscopy

          -  Body mass index &gt; = 40 kg/m2

          -  Informed consent signed

          -  Patient treated with intravenous administration of lidocaine

        Exclusion Criteria:

          -  Contraindication to lidocaine use (allergy, atrioventricular block, seizure,
             porphyria)

          -  Concomitant use of beta blocker and others anti arrhythmic drugs

          -  Cardiac or hepatic insufficiency

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas RIMMELE, MD, PhD</last_name>
    <phone>+33 4 72 11 02 81</phone>
    <email>thomas.rimmele@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin DELWARDE, MD, PhD</last_name>
    <phone>+33 4 72 11 62 76</phone>
    <email>benjamin.delwarde@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot - Département d'anesthésie réanimation</name>
      <address>
        <city>LYON cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas RIMMELE, MD, PhD</last_name>
      <phone>+33 4 72 11 02 81</phone>
      <email>thomas.rimmele@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Benjamin DELWARDE, MD, PhD</last_name>
      <phone>+33 4 72 11 62 76</phone>
      <email>benjamin.delwarde@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas RIMMELE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin DELWARDE, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>March 14, 2016</lastchanged_date>
  <firstreceived_date>August 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bariatric surgery, lidocaine, plasmatic concentration, MonoEthylGlycineXylidide (MEGx), safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
